Question

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

1 comment1

Total Forecasters41

Community Prediction80.8% (74% - 85%)

Make a Prediction

50%

community: 80.8%

Authors:

casens

Opened:

Closes:

Scheduled resolution:

Health & Pandemics

Food and Drug Administration

Medicare announces 15 new drugs up for price negotiations, including Ozempic

NBC•Jan 17, 2025

Ozempic and Wegovy selected for next round of Medicare drug price negotiations

CNN•Jan 17, 2025

Medicare to Negotiate Lower Prices for Weight-Loss Drugs

New York Times•Jan 17, 2025

Learn more about Metaculus NewsMatch

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

59.7%

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

43%

Comments

? comments

Authors:

casens

Opened:

Closes:

Scheduled resolution:

Health & Pandemics

Food and Drug Administration

Medicare announces 15 new drugs up for price negotiations, including Ozempic

NBC•Jan 17, 2025

Ozempic and Wegovy selected for next round of Medicare drug price negotiations

CNN•Jan 17, 2025

Medicare to Negotiate Lower Prices for Weight-Loss Drugs

New York Times•Jan 17, 2025

Learn more about Metaculus NewsMatch

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

59.7%

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

43%

📖 The ACX 2025 Prediction Contest Is Open!

🔭 The Bridgewater x Metaculus Forecasting Contest Goes Global — Feb 3

MetaculusM

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

Make a Prediction

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

Comments

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?